The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.
 
Young-Gyu Park
No Relationships to Disclose
 
Hyung-Don Kim
Honoraria - AstraZeneca Japan; Boostimmune; Boryung Pharmaceuticals; Bristol-Myers Squibb; Ono Pharmaceutical
 
Sejin Kim
No Relationships to Disclose
 
Kyu-Pyo Kim
No Relationships to Disclose
 
Sook Ryun Park
Stock and Other Ownership Interests - Genome & Company
Honoraria - BMS Korea; ImmuneOncia Therapeutics Inc.; ImmuneOncia Therapeutics Inc.; ImmuneOncia Therapeutics Inc.; MSD
Consulting or Advisory Role - BeiGene; Pfizer Pharmaceuticals Korea Ltd.
Research Funding - ImmuneOncia (Inst); Incyte (Inst); Ono Pharmaceutical
 
Min-Hee Ryu
Honoraria - AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Changhoon Yoo
Honoraria - AstraZeneca; Bayer; Boryung Pharmaceuticals; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; MSD Oncology; Novartis; SERVIER
Research Funding - AstraZeneca; Bayer; SERVIER